A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma.


BACKGROUND Osteosarcoma is the most common primary malignant tumour in young adults. An effective treatment strategy for relapsed patients is still not defined. Pemetrexed is a multitargeted antifolate with a mode of action similar to, and a range of action broader than that of methotrexate. The primary objective of this phase II study was to determine… (More)
DOI: 10.1016/j.ejca.2011.12.015


5 Figures and Tables